These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 16427279)
1. Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. Antuch W; Menon S; Chen QZ; Lu Y; Sakamuri S; Beck B; Schauer-Vukasinović V; Agarwal S; Hess S; Dömling A Bioorg Med Chem Lett; 2006 Mar; 16(6):1740-3. PubMed ID: 16427279 [TBL] [Abstract][Full Text] [Related]
2. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929 [TBL] [Abstract][Full Text] [Related]
3. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183 [TBL] [Abstract][Full Text] [Related]
4. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface. Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783 [TBL] [Abstract][Full Text] [Related]
5. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Ernst JT; Becerril J; Park HS; Yin H; Hamilton AD Angew Chem Int Ed Engl; 2003 Feb; 42(5):535-9. PubMed ID: 12569483 [No Abstract] [Full Text] [Related]
6. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors. Yap JL; Cao X; Vanommeslaeghe K; Jung KY; Peddaboina C; Wilder PT; Nan A; MacKerell AD; Smythe WR; Fletcher S Org Biomol Chem; 2012 Apr; 10(15):2928-33. PubMed ID: 22395339 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. Doshi JM; Tian D; Xing C J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155 [TBL] [Abstract][Full Text] [Related]
8. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293 [TBL] [Abstract][Full Text] [Related]
9. Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles. Denisov AY; Chen G; Sprules T; Moldoveanu T; Beauparlant P; Gehring K Biochemistry; 2006 Feb; 45(7):2250-6. PubMed ID: 16475813 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activities of new di- and trimeric quinoline derivatives. Broch S; Hénon H; Debaud AL; Fogeron ML; Bonnefoy-Bérard N; Anizon F; Moreau P Bioorg Med Chem; 2010 Oct; 18(19):7132-43. PubMed ID: 20800501 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540 [TBL] [Abstract][Full Text] [Related]
12. Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2. Marcaurelle LA; Johannes C; Yohannes D; Tillotson BP; Mann D Bioorg Med Chem Lett; 2009 May; 19(9):2500-3. PubMed ID: 19329314 [TBL] [Abstract][Full Text] [Related]
14. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. Yin H; Hamilton AD Bioorg Med Chem Lett; 2004 Mar; 14(6):1375-9. PubMed ID: 15006365 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Rudner J; Elsaesser SJ; Müller AC; Belka C; Jendrossek V Biochem Pharmacol; 2010 Jan; 79(1):10-20. PubMed ID: 19665451 [TBL] [Abstract][Full Text] [Related]
16. Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist. Dömling A; Antuch W; Beck B; Schauer-Vukasinović V Bioorg Med Chem Lett; 2008 Jul; 18(14):4115-7. PubMed ID: 18583128 [TBL] [Abstract][Full Text] [Related]
17. Triggering of apoptosis by Puma is determined by the threshold set by prosurvival Bcl-2 family proteins. Callus BA; Moujallad DM; Silke J; Gerl R; Jabbour AM; Ekert PG; Vaux DL J Mol Biol; 2008 Dec; 384(2):313-23. PubMed ID: 18835564 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and molecular modeling study of new trimeric quinoline derivatives. Saugues E; Nauton L; Théry V; Anizon F; Moreau P Bioorg Chem; 2011 Aug; 39(4):143-50. PubMed ID: 21807395 [TBL] [Abstract][Full Text] [Related]
19. A putative role for human BFK in DNA damage-induced apoptosis. Ozören N; Inohara N; Núñez G Biotechnol J; 2009 Jul; 4(7):1046-54. PubMed ID: 19557800 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Konopleva M; Contractor R; Tsao T; Samudio I; Ruvolo PP; Kitada S; Deng X; Zhai D; Shi YX; Sneed T; Verhaegen M; Soengas M; Ruvolo VR; McQueen T; Schober WD; Watt JC; Jiffar T; Ling X; Marini FC; Harris D; Dietrich M; Estrov Z; McCubrey J; May WS; Reed JC; Andreeff M Cancer Cell; 2006 Nov; 10(5):375-88. PubMed ID: 17097560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]